Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Michael B. Atkins, Damla Günenç et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 21